$59.00
Manufacturer: Israel
Drugs used for intestinal infections. Antibiotics. Rifaximin. ATX code A07A A11.
- Gastrointestinal infections caused by rifaximin-susceptible bacteria, such as acute gastrointestinal infections and traveler’s diarrhea;
- bacterial overgrowth syndrome in the small intestine;
- hepatic encephalopathy;
- diverticular bowel disease (diverticulitis) in the acute stage and chronic inflammation of the intestine;
- prevention of infectious complications in colorectal surgery.
Description
Composition
active ingredient: rifaximin;
1 film-coated tablet contains 200 mg of rifaximin;
excipients: sodium starch (type A), glycerol distearate, colloidal silicon dioxide, talc, microcrystalline cellulose, hypromellose, titanium dioxide (E 171), trilon B, propylene glycol, iron oxide red (E 172).
Dosage form
Film-coated tablets.
Basic physical and chemical properties: pink round biconvex film-coated tablets.
Pharmacotherapeutic group
Drugs used for intestinal infections. Antibiotics. Rifaximin. ATX code A07A A11.
Pharmacodynamics
Alfa Normix contains the active substance rifaximin in the α polymorphic form. Rifaximin is a broad-spectrum antibiotic that is a semi-synthetic derivative of rifamycin SV. Like other rifamycins, it irreversibly binds the β-subunits of the bacterial DNA-dependent RNA polymerase and thus inhibits the synthesis of bacterial RNA and proteins. This irreversible binding to the enzyme leads to the bactericidal action of rifaximin against sensitive bacteria.
Rifaximin has a broad spectrum of antimicrobial activity against gram-positive and gram-negative aerobic and anaerobic bacteria that cause intestinal infections.
A wide range of antibacterial action of rifaximin leads to a decrease in the number of pathogenic bacteria in the intestine that cause certain diseases or are involved in their pathogenesis.
Rifaximin may reduce:
- the production of ammonia and other toxic compounds by bacteria occurs during the pathogenesis and development of clinical symptoms of hepatic encephalopathy in severe liver diseases with detoxification function disorders;
- bacterial hyperproliferation in intestinal bacterial overgrowth syndrome the
number of bacteria in intestinal diverticula, which can cause intraperidiverticular inflammation and probably significantly affect the development of symptoms and complications of diverticulosis; - antigenic stimuli that, in the presence of genetically determined defects in immunoregulation and / or barrier function of the intestinal mucosa, can provoke or maintain chronic intestinal inflammation;
- the risk of infectious complications in colorectal surgery.
Indications
- Gastrointestinal infections caused by rifaximin-susceptible bacteria, such as acute gastrointestinal infections and traveler’s diarrhea;
- bacterial overgrowth syndrome in the small intestine;
- hepatic encephalopathy;
- diverticular bowel disease (diverticulitis) in the acute stage and chronic inflammation of the intestine;
- prevention of infectious complications in colorectal surgery.
Contraindications
- Hypersensitivity to rifaximin, other its derivatives or to any of the excipients of the drug; hypersensitivity reactions include exfoliative dermatitis, angioedema and anaphylaxis;
- intestinal obstruction;
- severe ulcerative lesions of the intestine.
Dosage and administration
Adults and children over 12 years old: 1 tablet 3 times a day to 2 tablets 2-3 times a day (corresponds to a daily dose of 600-1200 mg of rifaximin).
The duration of treatment should not exceed 7 days and depends on the clinical response to treatment. A second course of treatment can be carried out with a break of 20-40 days.
The doses used and the frequency of administration may be changed on the advice of a physician.
Mode of application
Take orally with a glass of water. The drug can be taken regardless of food intake.
Separate groups of patients
Patients with liver disease
The available clinical data indicate an increase in the systemic exposure of rifaximin in patients with liver damage compared with healthy volunteers. Despite this, an increase in the systemic exposure of rifaximin in patients with liver damage should be considered taking into account the local action of the drug in the gastrointestinal tract and its low systemic bioavailability, as well as the available safety data when using rifaximin in patients with liver cirrhosis. Therefore, due to the local action, dose adjustment of rifaximin is not recommended in such patients.
Patients with kidney disease
There are no clinical data on the use of rifaximin in patients with kidney damage. Although no dose change is expected in these patients, the drug should be used with caution in patients with renal impairment.
Recent Reviews